Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

There are about $10.5 billion of biotech convertibles outstanding, roughly 3% of the $305 billion market, according to BofA Securities.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

9 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...